Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to HBVaxPro Challenge Dose in Adults ≥50
NCT01251276Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2010
- Primary completion
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of hepatitis B vaccine (recombinant) in hepatitis B (HBV), sponsored by Merck & Co.. Started Nov 2010; status: completed.
02
Drugs
hepatitis B vaccine (recombinant)
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT01251276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251276.